223 related articles for article (PubMed ID: 24879786)
1. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.
Papadatou I; Piperi C; Alexandraki K; Kattamis A; Theodoridou M; Spoulou V
Clin Infect Dis; 2014 Sep; 59(6):862-5. PubMed ID: 24879786
[TBL] [Abstract][Full Text] [Related]
2. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster.
Papadatou I; Lagousi T; Kattamis A; Spoulou V
Ann Hematol; 2019 Mar; 98(3):775-779. PubMed ID: 30683996
[TBL] [Abstract][Full Text] [Related]
3. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
Gaultier GN; McCready W; Ulanova M
BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
[TBL] [Abstract][Full Text] [Related]
4. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
Chen Z; Cox KS; Tang A; Roman J; Fink M; Kaufhold RM; Guan L; Xie A; Boddicker MA; Mcguinness D; Xiao X; Li H; Skinner JM; Verch T; Retzlaff M; Vora KA
BMC Infect Dis; 2018 Dec; 18(1):613. PubMed ID: 30509199
[TBL] [Abstract][Full Text] [Related]
6. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
[TBL] [Abstract][Full Text] [Related]
7. Long-lasting hyporesponsivenss induced by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in asplenic patients with β-thalassemia major.
Papadatou I; Orthopoulos G; Theodoridou M; Spoulou V
Vaccine; 2015 Jul; 33(32):3779-83. PubMed ID: 26144903
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
[TBL] [Abstract][Full Text] [Related]
9. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
[TBL] [Abstract][Full Text] [Related]
10. Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults.
Gaillat J
Med Mal Infect; 2013 Jun; 43(6):215-21. PubMed ID: 23769155
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
12. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
[TBL] [Abstract][Full Text] [Related]
13. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
[TBL] [Abstract][Full Text] [Related]
15. Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals.
Nived P; Jørgensen CS; Settergren B
Vaccine; 2015 Mar; 33(14):1688-94. PubMed ID: 25707692
[TBL] [Abstract][Full Text] [Related]
16. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.
van Westen E; Wijmenga-Monsuur AJ; van Dijken HH; van Gaans-van den Brink JA; Kuipers B; Knol MJ; Berbers GA; Sanders EA; Rots NY; van Els CA
Clin Infect Dis; 2015 Aug; 61(3):342-9. PubMed ID: 25838290
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.
Cripps AW; Folaranmi T; Johnson KD; Musey L; Niederman MS; Buchwald UK
Expert Rev Vaccines; 2021 Mar; 20(3):257-267. PubMed ID: 33567914
[No Abstract] [Full Text] [Related]
19. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
